Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Aug 10, 2026
USA Rare Earth (USAR) +3.9% Recovery Highlights Vertical Integration Strategy

USA Rare Earth (USAR) +3.9% Recovery Highlights Vertical Integration Strategy

Key Takeaways

  • USA Rare Earth (USAR) shares edged approximately 3.9% higher over the last 30 days, trading near $19.20, reflecting a modest recovery from July lows.
  • The company is aggressively executing a mine-to-magnet vertical integration strategy, anchored by its Stillwater, Oklahoma magnet manufacturing facility and multiple high-profile acquisitions.
  • Key transactions include the $2.8 billion Serra Verde acquisition in Brazil, the Texas Mineral Resources merger, a stake in France's Carester, and the earlier purchase of UK-based Less Common Metals.
  • A $1.6 billion funding package with the U.S. Department of Commerce underscores strong government support for domestic rare earth supply chain development.
  • Analyst consensus rates USAR a Moderate Buy with an average price target near $35.83, though the company remains pre-revenue at scale and carries significant execution risk.
  • Q2 2026 earnings are scheduled for release after market close on August 10, 2026, with analysts projecting an EPS loss of $0.19 on modest revenue of $6.45 million.

Current Market Snapshot

USA Rare Earth (USAR) has experienced a turbulent 2026. After trading above $27 in early June, the stock endured a sharp multi-week pullback that pushed shares toward the $13–$15 range by late July. A recent recovery has lifted USAR back near the $19 level, driven largely by progress on strategic initiatives and renewed investor interest ahead of the company's Q2 earnings release. The broader critical minerals sector remains in focus as U.S. policymakers prioritize reducing dependence on China's dominance in rare earth processing, which accounts for roughly 90% of global supply. Against this backdrop, USAR's market capitalization sits at approximately $4.3 billion, with a 52-week range spanning $11.45 to $43.98.

Business Overview and Competitive Position

USA Rare Earth, Inc. is building a fully integrated rare earth and permanent magnet value chain spanning mining, processing, metal-making, alloy production, and neodymium (NdFeB) magnet manufacturing. Headquartered in Stillwater, Oklahoma, the company holds mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas—one of North America's most significant rare earth projects. The company went public in March 2025 through a merger with Inflection Point Acquisition Corp. II. Its products serve aerospace and defense, semiconductors, data centers, electric vehicles, healthcare, and industrial sectors. Through its aggressive M&A strategy, USAR now operates across the United States, United Kingdom, France, and Brazil, positioning itself as one of the few Western-aligned alternatives to China's rare earth supply chain.

Recent Developments Driving USAR

USA Rare Earth has been one of the most active dealmakers in the critical minerals space over the past several months. In March 2026, Phase 1a of its Stillwater magnet production line was commissioned, targeting 600 metric tons of annual capacity by year-end, with customer-ready production expected in the second half of the year. The company also reached an agreement to merge with Texas Mineral Resources Corp., consolidating full economic ownership of the Round Top Project in an all-stock deal valued at approximately $73 million.

In April 2026, USAR announced its largest transaction to date: a $2.8 billion cash-and-stock acquisition of Brazil's Serra Verde Group, owner of the Pela Ema rare earth mine—the only scaled producer of all four magnetic rare earth elements outside Asia. The deal includes a 15-year offtake agreement with a U.S. government-backed special purpose vehicle. That same month, USAR acquired a roughly 12.5% stake in French rare earth processing firm Carester SAS. These moves follow the November 2025 acquisition of Less Common Metals, a leading UK-based producer of rare earth metals and alloys. In January 2026, the company completed a $1.5 billion PIPE financing and entered into a $1.6 billion letter of intent with the U.S. Department of Commerce.

On the analyst front, USAR carries a Moderate Buy consensus rating with price targets ranging from $30 to $40. Analysts at Wedbush raised their target to $35, while Cantor Fitzgerald reiterated an Overweight rating with a $40 target. However, Roth Capital and Needham trimmed their targets to $30 and $33, respectively, reflecting caution around near-term execution and dilution risks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

2026 Outlook and What Investors Should Watch

Several catalysts and risks will shape USAR's trajectory through the remainder of 2026. The immediate focus is the Q2 2026 earnings release, which should provide updates on Stillwater's production ramp, cash burn rates, and progress toward finalizing the Department of Commerce funding agreement. The anticipated closing of the Serra Verde acquisition in Q3 2026 represents another pivotal milestone, as it would transform USAR into a multi-continent operator with an active producing mine. Investors should also monitor the definitive feasibility study for Round Top, the ramp-up of the Carester processing facility toward year-end, and any further dilution from share issuance tied to acquisition financing. Macroeconomic factors—including rare earth pricing trends, U.S.-China trade policy, and federal funding for critical minerals—will continue to influence sector sentiment. Execution risk remains the central challenge: translating ambitious blueprints into operational cash flow is a multi-year proposition with no guarantee of success. From what I see, this is important because the company is still pre-revenue at scale.

Exploring AI Tools in My Research

In my own analysis of volatile sectors like critical minerals, I regularly use Tickeron’s AI Trading Bots to review algorithmic strategies across different timeframes and risk profiles. The platform offers transparency into historical performance and real-time signals, which helps me evaluate approaches that align with my views on stocks like USAR.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: USAR

Contributor

Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.


USAR's RSI Indicator ascending out of oversold territory

The RSI Oscillator for USAR moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 8 similar instances when the indicator left oversold territory. In of the 8 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on USAR as a result. In of 41 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for USAR just turned positive on July 31, 2026. Looking at past instances where USAR's MACD turned positive, the stock continued to rise in of 32 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where USAR advanced for three days, in of 127 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where USAR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

USAR broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for USAR entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. USAR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.518) is normal, around the industry mean (11.557). P/E Ratio (20.267) is within average values for comparable stocks, (130.643). USAR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (0.295). USAR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.025). P/S Ratio (344.828) is also within normal values, averaging (294.079).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. USAR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are BHP Group Limited (NYSE:BHP), Vale SA (NYSE:VALE).

Industry description

The category includes companies that explore for, mine and extract metals, such as copper, diamonds, nickel, cobalt ore, lead, zinc and uranium. BHP, Rio Tinto and Southern Copper Corporation are major players in this space.

Market Cap

The average market capitalization across the Other Metals/Minerals Industry is 9.45B. The market cap for tickers in the group ranges from 230 to 225B. BHP holds the highest valuation in this group at 225B. The lowest valued company is BAJFF at 230.

High and low price notable news

The average weekly price growth across all stocks in the Other Metals/Minerals Industry was 16%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -17%. WWR experienced the highest price growth at 86%, while EMAT experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Other Metals/Minerals Industry was 176%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 92
Profit Risk Rating: 87
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
USAR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry OtherMetalsMinerals

Profile
Details
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.